How have ASPCF shares performed in 2024?

Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2024. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22. View the best growth stocks for 2024 here .

When did Acerus Pharmaceuticals' stock split?

Shares of Acerus Pharmaceuticals reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ASPCF

Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free ASPCF Stock Alerts

$0.22

0.00 (0.00%)

(As of 07/21/2023)

Compare

Today's Range: $0.22
▼
$0.22
50-Day Range: $0.22
▼
$0.22
52-Week Range: $0.22
▼
$8.16

Volume: N/A
Average Volume: 1,500 shs
Market Capitalization: $1.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Acerus Pharmaceuticals alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF)

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

ASPCF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASPCF Stock News Headlines

March 14, 2023 | finance.yahoo.com

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process

January 16, 2023 | theglobeandmail.com

Acerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 15, 2022 | finance.yahoo.com

Acerus Reports Third Quarter 2022 Financial Results

October 3, 2022 | finance.yahoo.com

Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders

September 21, 2022 | marketwatch.com

Acerus Pharmaceuticals to Initiate Strategic Review of Operations

September 21, 2022 | finance.yahoo.com

Acerus Announces Initiation of Strategic Review

August 23, 2022 | seekingalpha.com

Acerus Pharmaceuticals CFO resigns effective November 20, 2022

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

August 14, 2022 | seekingalpha.com

Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript

August 5, 2022 | finance.yahoo.com

Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders

June 27, 2022 | finance.yahoo.com

Acerus Announces Voting Results for the 2022 Annual Meeting

June 24, 2022 | seekingalpha.com

Acerus Pharmaceuticals increases loan facility to $37.94M

May 11, 2022 | seekingalpha.com

Acerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78M

May 5, 2022 | finance.yahoo.com

Acerus To Report Q1-2022 Financial Results And Host Investor Call

April 26, 2022 | finance.yahoo.com

Acerus Announces Completion of Share Consolidation

April 19, 2022 | finance.yahoo.com

Acerus Announces Share Consolidation

February 28, 2022 | seekingalpha.com

Acerus to acquire Florida-based Serenity in cash/stock deal

February 28, 2022 | stockhouse.com

Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva(TM)

February 28, 2022 | finance.yahoo.com

Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™

See More Headlines

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:ASPCF
CUSIP: N/A
CIK: N/A
Web: www.aceruspharma.com
Phone: (416) 679-0771
Fax: 905-569-1809
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,820,000.00
Net Margins: -924.33%
Pretax Margin: -924.33%
Return on Equity: N/A
Return on Assets: -74.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.67
Quick Ratio: 0.34

Sales & Book Value

Annual Sales: $2.12 million
Price / Sales: 0.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.38) per share
Price / Book: -0.07

Miscellaneous

Outstanding Shares: 7,708,000
Free Float: N/A
Market Cap: $1.70 million
Optionable: Not Optionable
Beta: 0.69

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Edward Gudaitis
President, CEO & Non-Independent Director
Naveed Manzoor
Chief Financial Officer
Christopher Sorli
Chief Medical Officer
Philippe Savard
Secretary, Senior Vice President & General Counsel
Chris Witty
Investor Relations Contact

Key Competitors

View All Competitors

ASPCF Stock Analysis - Frequently Asked Questions

How have ASPCF shares performed in 2024?: Acerus Pharmaceuticals' stock was trading at $0.22 at the beginning of 2024. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22.
View the best growth stocks for 2024 here.
When did Acerus Pharmaceuticals' stock split?: Shares of Acerus Pharmaceuticals reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Acerus Pharmaceuticals?: Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ASPCF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial